IRIS PubliCatt

Colafigli, Manuela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 2.523
NA - Nord America 2.137
AS - Asia 573
AF - Africa 7
SA - Sud America 7
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 1
Totale 5.253
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.120
DE - Germania 825
SE - Svezia 363
FR - Francia 342
PL - Polonia 318
CN - Cina 298
UA - Ucraina 231
IT - Italia 174
IE - Irlanda 99
SG - Singapore 87
GB - Regno Unito 66
ID - Indonesia 59
IN - India 56
FI - Finlandia 51
TR - Turchia 40
RU - Federazione Russa 28
CA - Canada 16
IR - Iran 8
BE - Belgio 7
HK - Hong Kong 7
EU - Europa 5
JP - Giappone 5
NL - Olanda 4
VN - Vietnam 4
CZ - Repubblica Ceca 3
KR - Corea 3
BG - Bulgaria 2
BR - Brasile 2
CI - Costa d'Avorio 2
CL - Cile 2
DK - Danimarca 2
ET - Etiopia 2
NO - Norvegia 2
PE - Perù 2
PH - Filippine 2
AR - Argentina 1
AT - Austria 1
AU - Australia 1
BN - Brunei Darussalam 1
CH - Svizzera 1
EE - Estonia 1
GR - Grecia 1
IM - Isola di Man 1
IS - Islanda 1
MA - Marocco 1
MM - Myanmar 1
MX - Messico 1
NG - Nigeria 1
PK - Pakistan 1
TN - Tunisia 1
TW - Taiwan 1
Totale 5.253
Salva come PNG Salva come JPEG
Città #
Chandler 469
Kraków 317
Ashburn 167
Jacksonville 163
New York 125
San Mateo 120
Dublin 97
Nanjing 90
Dearborn 73
Wilmington 62
Jakarta 59
Houston 58
Singapore 56
Ann Arbor 54
Nürnberg 47
Lawrence 45
Cattolica 43
Milan 42
Redmond 41
Boston 40
Izmir 40
Nanchang 37
Woodbridge 32
Redwood City 29
Lancaster 22
Bremen 21
Moscow 20
Changsha 19
Fairfield 19
Munich 19
University Park 17
Shenyang 16
Los Angeles 15
Princeton 15
Boardman 13
Hebei 13
Kunming 13
Ottawa 13
Beijing 12
Mountain View 12
Seattle 12
Fremont 11
Marseille 11
Norwalk 11
Leawood 10
Chicago 9
Falls Church 9
Jinan 9
Verona 9
Augusta 8
Guangzhou 8
Jiaxing 8
Rome 8
Shanghai 8
Brussels 7
Hangzhou 7
Pune 7
Washington 7
Hong Kong 6
Simi Valley 6
Cambridge 5
Changchun 5
San Francisco 5
Tianjin 5
Zhengzhou 5
Andover 4
Busto Arsizio 4
Carate Brianza 4
Hanoi 4
Helsinki 4
Philadelphia 4
Tavagnacco 4
Amsterdam 3
Berlin 3
Detroit 3
Edinburgh 3
Fuzhou 3
Hefei 3
Modena 3
Paris 3
Sacramento 3
San Jose 3
Toronto 3
Turin 3
Abidjan 2
Atlanta 2
Auburn Hills 2
Bari 2
Buffalo 2
Clearwater 2
Cupertino 2
Faenza 2
Formia 2
Indiana 2
Kish 2
Lanzhou 2
Las Vegas 2
Lima 2
Mcallen 2
New Orleans 2
Totale 2.857
Salva come PNG Salva come JPEG
Nome #
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 195
Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis 173
Evaluation of emotion processing in HIV-infected patients and correlation with cognitive performance 146
Safety and efficacy of treatment switch to raltegravir plus tenofovir/emtricitabine or abacavir/lamivudine in patients with optimal virological control: 48-week results from a randomized pilot study (Raltegravir Switch for Toxicity or Adverse Events, RASTA Study) 146
Revised central nervous system neuropenetration-effectiveness score is associated with cognitive disorders in HIV-infected patients with controlled plasma viraemia 139
Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study 137
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2 years follow-up in HIV-infected patients 136
Evolution of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy from 2000 to 2010. 131
Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients 130
Neuropsychological screening tools in Italian HIV+ patients: a comparison of Montreal Cognitive Assessment (MoCA) and Mini Mental State Examination (MMSE) 128
Ophthalmic artery resistance index IS increased in HIV-Infected patients and is influenced by protease inhibitors exposure 121
Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination antiretroviral regimen. 119
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial 116
The association of high-sensitivity c-reactive protein and other biomarkers with cardiovascular disease in patients treated for HIV: a nested case-control study 109
Predictors of successful genotype-guided antiretroviral therapy in treatment-experienced individuals over calendar year: a cohort study 104
The effect of polymorphisms in candidate genes on the long-term risk of lipodystrophy and dyslipidemia in HIV-infected white patients starting antiretroviral therapy 104
Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study 104
Cardiovascular risk factors and carotid intima-media thickness are associated with low cognitive performance in HIV-infected patients 103
Relationship between self-reported adherence, antiretroviral drug concentration measurement and self-reported symptoms in patients treated for HIV-1 infection 102
Predictors of first-line antiretroviral therapy discontinuation due to drug-related adverse events in HIV-infected patients: a retrospective cohort study 99
Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients 97
HIV-infected patients show impaired cellular immune response to influenza vaccination, compared to healthy subjects 97
Are mutations in HIV type-1 reverse transcriptase 245 codon predictive of abacavir hypersensitivity reaction? 95
Virological suppression reduces clinical progression in patients with multiclass-resistant HIV type 1 95
Increased ophthalmic artery resistance index is associated with cognitive impairment in HIV-infected patients. 93
HIV-infected patients show impaired cellular immune response to influenza vaccination compared to healthy subjects 92
Baseline CD4(+) T-cell count and cardiovascular risk factors predict the evolution of cognitive performance during 2-year follow-up in HIV-infected patients 91
Lipid-lowering effect and changes in estimated cardiovascular risk after switching to a tenofovir-containing regimen for the treatment of HIV-infected patients 88
Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M) 88
Declining prevalence of HIV-1 drug resistance in treatment-failing patients: a clinical cohort study. 87
Mid-dosing interval concentration of atazanavir and virological outcome in patients treated for HIV-1 infection. 85
Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. 83
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: a multicenter analysis 83
Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazanavir and Lamivudine for treatment Simplification, AtLaS pilot study) 82
Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-Week results of a randomized trial 82
Prevalence of transmitted HIV-1 drug resistance in HIV-1 infected patients in Italy: evolution over 12 years and predictors 80
Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping 77
Cardiovascular risk factors and carotid intima-media thickness are associated with lower cognitive performance in HIV-infected patients 77
Long term follow-up of Nevirapine-treated patients in a single centre cohort 76
Switching to boosted protease inhibitor plus a second antiretroviral drug (dual therapy) for treatment simplification: A multicenter observational study 76
Interpretation systems for genotypic drug resistance of HIV-1 73
Exposure to abacavir and biomarkers of cardiovascular disease in HIV-1-infected patients on suppressive antiretroviral therapy: a longitudinal study 72
Exploratory analysis for the evaluation of estimated glomerular filtration rate, cholesterol and triglycerides after switching from tenofovir/emtricitabine plus atazanavir/ritonavir (ATV/r) to abacavir/lamivudine plus ATV/r in patients with preserved renal function 72
A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients 70
Improved interpretation of genotypic changes in the HIV-1 reverse transcriptase coding region that determine the virological response to didanosine 68
Genotypic resistance to lopinavir and fosamprenavir with or without ritonavir of clinical isolates from patients failing protease inhibitors-containing HAART regimens: prevalence and predictors 68
SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV 67
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016 66
Performance of genotypic tropism testing on proviral DNA in clinical practice: results from the DIVA study group 65
Viro-immunological efficacy and tolerability of dolutegravir-based regimens compared to regimens based on other integrase strand inhibitors, protease inhibitors, non-nucleoside reverse transcriptase inhibitors in patients with acute HIV-1 infection: a multicenter retrospective cohort study 54
The Effect of Switching to Maraviroc + Darunavir/Ritonavir Dual Therapy in Virologically Suppressed Patients on the Progression of Liver Fibrosis: Findings From a Randomized Study 52
Genotypic testing on HIV-1 DNA as a tool to assess HIV-1 co-receptor usage in clinical practice: results from the DIVA study group 47
Efficacy and durability of two- vs. three-drug integrase inhibitor-based regimens in virologically suppressed HIV-infected patients: Data from real-life ODOACRE cohort 47
Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study 42
Combining epidemiological and genetic networks signifies the importance of early treatment in HIV-1 transmission 40
Overall Tolerability of Integrase Inhibitors in Clinical Practice: Results from a Multicenter Italian Cohort 38
Survival in HIV-infected patients after a cancer diagnosis in the cART era: Results of an Italian multicenter study 37
Biochemical and inflammatory modifications after switching to dual antiretroviral therapy in HIV-infected patients in Italy: A multicenter retrospective cohort study from 2007 to 2015 32
Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy 27
Totale 5.303
Salva come PNG Salva come JPEG
Categoria #
all - tutte 18.617
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 18.617
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020497 0 0 42 22 59 86 37 49 53 43 53 53
2020/2021471 12 52 14 48 53 31 49 8 82 16 91 15
2021/2022555 51 52 13 41 24 28 9 104 17 46 72 98
2022/20231.141 170 177 82 185 82 143 25 92 129 5 38 13
2023/2024570 19 151 9 59 23 169 17 4 6 9 69 35
2024/2025114 17 29 68 0 0 0 0 0 0 0 0 0
Totale 5.303